---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264690"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:36:50.550512+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced

## Summary
- Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.
- Delivered 4,388 clinical tests, +26% sequential and +364% YoY; submitted third Medicare dossier for lung cancer.
- FY 2025 revenue guidance narrowed to $68-73M (from $70-80M); clinical tests reimbursed cut to $1.5-2M from $3-6M.
- Cash, cash equivalents and investments $150.5M; cash used in operations and capex $23.4M in Q3.
- Q4 2025 revenue outlook $15.7-20.7M; pharma/services revenue $12-17M; population sequencing ~$3.7M.

## SEC filing metadata
- accession: 0001193125-25-264690
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525264690/0001193125-25-264690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525264690/psnl-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264690
- JSON: https://secwatch.observer/filing/0001193125-25-264690.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.